These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38431781)

  • 1. Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer.
    Wang C; Shi Q; Zhang G; Wu X; Yan W; Wan A; Xiong S; Yuan L; Tian H; Ma D; Jiang J; Qi X; Zhang Y
    Oncologist; 2024 May; 29(5):e635-e642. PubMed ID: 38431781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxane combined with lobaplatin or anthracycline for neoadjuvant chemotherapy of triple-negative breast cancer: a randomized, controlled, phase II study.
    Wang C; Yuan L; Wu X; Wang Y; Tian H; Zhang G; Wan A; Xiong S; Wang C; Zhou Y; Ma D; Bao Y; Qu M; Jiang J; Zhang Y; Qi X
    BMC Med; 2024 Jun; 22(1):252. PubMed ID: 38886794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of neutrophil/lymphocyte ratio and platelet/lymphocyte ratio with ER and PR in breast cancer patients and their changes after neoadjuvant chemotherapy.
    Xu J; Ni C; Ma C; Zhang L; Jing X; Li C; Liu Y; Qu X
    Clin Transl Oncol; 2017 Aug; 19(8):989-996. PubMed ID: 28247194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for response to neoadjuvant chemotherapy: inflammatory and immune markers in triple-negative breast cancer.
    Kusama H; Kittaka N; Soma A; Taniguchi A; Kanaoka H; Nakajima S; Oyama Y; Seto Y; Okuno J; Watanabe N; Matsui S; Nishio M; Fujisawa F; Honma K; Tamaki Y; Nakayama T
    Breast Cancer; 2023 Nov; 30(6):1085-1093. PubMed ID: 37782377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer.
    Al Jarroudi O; El Bairi K; Abda N; Zaimi A; Jaouani L; Chibani H; Afqir S
    Biomark Med; 2021 Oct; 15(14):1289-1298. PubMed ID: 34486882
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
    Wu X; Tang P; Li S; Wang S; Liang Y; Zhong L; Ren L; Zhang T; Zhang Y
    Nat Commun; 2018 Feb; 9(1):832. PubMed ID: 29483583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet/Lymphocyte Ratio Is Superior to Neutrophil/Lymphocyte Ratio as a Predictor of Chemotherapy Response and Disease-free Survival in Luminal B-like (HER2
    Hu Y; Wang S; Ding N; Li N; Huang J; Xiao Z
    Clin Breast Cancer; 2020 Aug; 20(4):e403-e409. PubMed ID: 32201163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy.
    Jia W; Yuan L; Ni H; Xu B; Zhao P
    Technol Cancer Res Treat; 2021; 20():15330338211034291. PubMed ID: 34308689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
    Asano Y; Kashiwagi S; Onoda N; Noda S; Kawajiri H; Takashima T; Ohsawa M; Kitagawa S; Hirakawa K
    Ann Surg Oncol; 2016 Apr; 23(4):1104-10. PubMed ID: 26511266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil-lymphocyte ratio predicts response to chemotherapy in triple-negative breast cancer.
    Chae S; Kang KM; Kim HJ; Kang E; Park SY; Kim JH; Kim SH; Kim SW; Kim EK
    Curr Oncol; 2018 Apr; 25(2):e113-e119. PubMed ID: 29719435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
    Pang J; Zhou H; Dong X; Wang S; Xiao Z
    Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    Wu Y; Li C; Zhao J; Yang L; Liu F; Zheng H; Wang Z; Xu Y
    World J Surg Oncol; 2016 Nov; 14(1):289. PubMed ID: 27852294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
    Vernieri C; Mennitto A; Prisciandaro M; Huber V; Milano M; Rinaldi L; Cona MS; Maggi C; Ferrari B; Manoukian S; Mariani G; Bianchi G; Capri G; Rivoltini L; de Braud F
    Sci Rep; 2018 Jun; 8(1):8703. PubMed ID: 29880896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of the peripheral platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in predicting pathologic complete response after neoadjuvant chemotherapy in breast cancer patients.
    Jin X; Wang K; Shao X; Huang J
    Gland Surg; 2022 Jun; 11(6):1057-1066. PubMed ID: 35800742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer.
    Lou C; Jin F; Zhao Q; Qi H
    Am J Transl Res; 2022; 14(5):3240-3246. PubMed ID: 35702128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience.
    Dogan M; Eren T; Ozdemir N; Cigirgan CL; Zengin N
    Saudi J Gastroenterol; 2015; 21(5):320-4. PubMed ID: 26458860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.